10-Q: Virpax Pharmaceuticals Reports Q1 2024 Results, Faces Going Concern Uncertainty

Virpax Pharmaceuticals reported a net loss of $3.2 million for the first quarter of 2024 and faces substantial doubt about its ability to continue as a going concern due to ongoing losses and cash obligations.

Summary

• Virpax Pharmaceuticals, a preclinical-stage company, reported a net loss of $3.2 million for the three months ended March 31, 2024, compared to a $1.5 million loss in the same period of 2023.
• The company's operating expenses totaled $3.3 million, with general and administrative expenses increasing significantly due to a prior year insurance reimbursement.
• Research and development expenses increased to $1.6 million, primarily driven by activities related to their lead product candidate, Probudur.
• As of March 31, 2024, Virpax had a cash balance of $1.9 million, which is insufficient to sustain operations through the second quarter of 2024.
• The company is obligated to pay $2.5 million by July 1, 2024, as part of a settlement agreement, and needs to raise additional capital to fund operations.
• There is substantial doubt about the company's ability to continue as a going concern due to ongoing losses and cash obligations.
• The company's accumulated deficit has reached $62.8 million as of March 31, 2024.
• Virpax is exploring licensing and strategic partnerships for some of its assets to focus on its prescription drug pipeline.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with significant losses, a weak cash position, and substantial doubt about the company's ability to continue as a going concern. While there is some progress in research and development, the overall outlook is negative due to the financial challenges and the need for a significant capital raise.

Positives

• The company has made progress in the development of Probudur, with IND enabling studies started.
• Virpax has completed four in vitro studies and in vivo acute efficacy studies for Envelta.
• The company has engaged Destum Partners to search for a Global Animal Healthcare sublicensing partner for NobrXiol.
• Preclinical virology study results for AnQlar support its proposed mechanism of action as a prophylactic viral barrier.

Negatives

• The company has a significant net loss of $3.2 million for the quarter.
• Virpax has a limited cash position of $1.9 million, which is insufficient to sustain operations through the second quarter of 2024.
• The company is obligated to pay $2.5 million by July 1, 2024, as part of a settlement agreement.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has an accumulated deficit of $62.8 million.
• The company is facing potential litigation costs with its former CEO.

Risks

• The company's ability to continue as a going concern is in doubt due to ongoing losses and cash obligations.
• Virpax needs to raise substantial additional capital to fund operations, including a $2.5 million settlement payment and potential litigation costs with its former CEO.
• There is no assurance that the company's research and development projects will be successful or that products will obtain regulatory approval.
• The company is dependent on third parties for manufacturing and clinical trials.
• The company's ability to maintain its Nasdaq listing is at risk due to not meeting the minimum stockholders equity requirement.
• Global macroeconomic conditions, including the war in the Middle East, could disrupt the company's operations and supply chains.
• The company may be forced to curtail spending in research and development activities in order to conserve cash.

Future Outlook

The company anticipates incurring additional losses until it can generate significant revenue from its product candidates. They will need to raise substantial additional capital to fund operations, including a $2.5 million settlement payment, and to complete clinical development and commercialization of their product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.

Management Comments

• The company is focused on developing novel and proprietary drug delivery systems across various pain indications.
• The company believes Probudur has the potential to eliminate or significantly reduce the need to prescribe opioids for postoperative pain relief.
• The company is seeking to license out or partner its AnQlar and Epoladerm assets to focus on its prescription drug pipeline.

Industry Context

The company operates in the pharmaceutical industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The company's focus on non-opioid pain management aligns with a growing trend in the industry to address the opioid crisis. The company's development of novel drug delivery systems is also a key area of innovation in the pharmaceutical sector.

Comparison to Industry Standards

• Virpax's financial situation is concerning compared to industry standards for publicly traded biotech companies, particularly those in the clinical stage.
• Many comparable companies have a stronger cash position and a longer runway to fund operations and clinical trials.
• For example, companies like Biohaven Pharmaceuticals (now part of Pfizer) and Axsome Therapeutics, which have successfully developed and commercialized CNS drugs, had significantly more robust financial resources during their development phases.
• Virpax's reliance on external funding and the uncertainty surrounding its ability to raise capital are significant risks compared to companies with established revenue streams or strong investor backing.
• The company's burn rate of approximately $1 million per month is high for a preclinical stage company, and its cash position is insufficient to meet its near-term obligations.
• The settlement payment of $6 million is a significant financial burden for a company of Virpax's size and stage of development.
• The company's research and development expenses are in line with other preclinical stage companies, but its overall financial health is weaker than many of its peers.

Management Changes

Legal Proceedings

• The company entered into a settlement agreement with Sorrento and Scilex to resolve all claims related to a litigation.
• The company agreed to pay $6 million in total, with $3.5 million paid in March 2024 and $2.5 million due by July 1, 2024.
• The company also agreed to pay royalties of 6% of annual net sales of products developed from Epoladerm, Probudur, and Envelta.
• The company is facing potential litigation costs with its former CEO, Anthony P. Mack, related to indemnification and contribution claims.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the potential for dilution from a capital raise.
• Employees may be impacted by potential cost-cutting measures or layoffs if the company cannot secure additional funding.
• Customers and patients may be affected by delays in the development and commercialization of the company's product candidates.
• Suppliers and creditors may face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to raise additional capital to fund operations and make the $2.5 million settlement payment.
• The company plans to submit a plan to Nasdaq to regain compliance with the minimum stockholders equity requirement.
• The company will continue to develop its product candidates, including Probudur, Envelta, and NobrXiol.
• The company is seeking to license out or partner its AnQlar and Epoladerm assets.
• The company anticipates filing an IND for Probudur in 2024, but this may be adjusted due to the war in the Middle East.
• The company anticipates filing an IND for Envelta in 2024, but this may be extended into 2025.

Key Dates

Keywords

pharmaceuticals, biotechnology, drug delivery, pain management, central nervous system, Probudur, Envelta, AnQlar, Epoladerm, NobrXiol, clinical trials, regulatory approval, going concern, capital raise, settlement agreement